In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background: Second-generation long-acting insulin glargine 300 U/mL (Gla-300) and degludec 100 U/mL (Deg-100) provide novel basal insulin therapies for the treatment of type 1 diabetes (T1D). Both offer a flatter pharmacokinetic (PK) profile than the previous generation of long-acting insulins, thus improving glycemic control while reducing hypoglycemic events. This work describes an in silico head-to-head comparison of the two basal insulins on 24-h glucose profiles and was used to guide the design of a clinical trial. Materials and Methods: The Universities of Virginia (UVA)/Padova T1D simulator describes the intra-/interday variability of glucose-insulin dynamics and thus provides a robust bench-test for assessing glucose control for basal insulin therapies. A PK model describing subcutaneous absorption of Deg-100, in addition to the one already available for Gla-300, has been developed based on T1D clinical data and incorporated into the simulator. One hundred in silico T1D subjects received a basal insulin dose (Gla-300 or Deg-100) for 12 weeks (8 weeks uptitration, 4 weeks stable dosing) by morning or evening administration in a basal/bolus regimen. The virtual patients were uptitrated to their individual doses with two different titration rules. Results: The last 2-week simulated continuous glucose monitoring data were used to calculate various outcome metrics for both basal insulin treatments, with primary outcome being the percent time in glucose target (70–140 mg/dL). The simulations show no statistically significant difference for Gla-300 versus Deg-100 in the main endpoints. Conclusions: This work suggests comparable glucose control using either Gla-300 or Deg-100 and was used to guide the design of a clinical trial intended to compare second-generation long-acting insulin analogues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 2×
“13 Outcome metrics and statistical analysis Efficacy of glucose control was assessed by calculating the standard outcome metrics proposed in Danne et al. 37 from the last 2 weeks of CGM data.”
Self-citationMeal Simulation Model of the Glucose-Insulin System
Dalla Man, C., Rizza, R. A., & Cobelli, C. (2007) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2007.893506 · Cited by 955
Self-citationIn Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes
Kovatchev, B. P., Breton, M., Dalla Man, C., & Cobelli, C. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300106 · Cited by 760
Self-citationUnderstanding Equivalence and Noninferiority Testing
Walker, E., & Nowacki, A. S. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1513-8 · Cited by 751 · cited 1×
“This is sometimes implicitly set to be ‘‘Treatment A is equal to Treatment B,’’ thus finding a P > 0.05 does not necessarily mean that Treatment A is not inferior to Treatment B. 39 Thus, we performed a noninferiority test on the primary outcome and found that Gla-300 is not worse than Deg-100.”
InfluentialArtificial Pancreas: Past, Present, Future
Cobelli, C., Renard, E., & Kovatchev, B. (2011) · Diabetes · doi:10.2337/db11-0654 · Cited by 600
Self-citationDesign of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448
Becker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407
Heller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., Renard, E., Russell-Jones, D., Philotheou, A., Francisco, A. M. O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60204-9 · Cited by 402 · cited 1×
“…24h,Gla - 300 = Ins-AUC 0 (cid:2) 24h,Gla - 300 (1) IN SILICO COMPARISON OF INSULIN GLA-300 AND DEG-100 formulations and injection schedules, two different basal insulin titration rules were implemented, with titration rules A and B derived from Home et al. 11 and Heller et al., 35 respectively.”
Heise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397 · cited 1×
“6,7 8–10 In addition, for both the second-generation long-acting insulins, less hypoglycemic events and noninferiority in terms of HbA1c reduction were shown.”
Ratner, R. E., Gough, S. C. L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12032 · Cited by 346
Research works printed but not linked: 22
- 10.1007/s11892-017-0926-8 · DOI
- 10.1016/j.diabet.2013.09.003 · DOI
- 10.1111/dom.12782 · DOI · Paper page
- 10.1080/17425255.2016.1202916 · DOI
- 10.1007/s40265-013-0051-1 · DOI
- 10.1517/17425255.2015.1058779 · DOI · Paper page
- 10.2337/dc15-0249 · DOI · Paper page
- 10.1111/dom.12938 · DOI · Paper page
- 10.1016/j.diabet.2017.10.001 · DOI · Paper page
- 10.1177/1932296817731422 · DOI · Paper page
- 10.2337/dc18-0559 · DOI · Paper page
- 10.1109/TBME.2019.2919250 · DOI
- 10.1109/TBME.2017.2652062 · DOI · Paper page
- 10.1109/TBME.2017.2784101 · DOI · Paper page
- Cobelli C Carson ER: Introduction to Modeling of Metabolic in Physiology and Medicine 2nd ed. San Diego CA: Academic Press 2019. · doi:10.1016/b978-0-12-815756-5.00001-1
- 10.1152/ajpendo.00473.2004 · DOI · Paper page
- 10.2337/dc16-0684 · DOI · Paper page
- 10.1109/TBME.2017.2746340 · DOI · Paper page
- 10.1155/2015/281589 · DOI
- 10.1111/dom.12416 · DOI · Paper page
- 10.1080/10273660008833060 · DOI · Paper page
- 10.1177/0954411917702931 · DOI · Paper page
Cited by
Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility
Cobelli, C., & Kovatchev, B. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231195081 · Cited by 46
Self-citationFaggionato, E., Schiavon, M., & Dalla Man, C. (2021) · Metabolites · doi:10.3390/metabo11040235 · Cited by 15
Self-citationSchiavon, M., Galderisi, A., Basu, A., Kudva, Y. C., Cengiz, E., & Dalla Man, C. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0397 · Cited by 8
Self-citationModeling Intraperitoneal Insulin Absorption in Patients with Type 1 Diabetes
Schiavon, M., Cobelli, C., & Dalla Man, C. (2021) · Metabolites · doi:10.3390/metabo11090600 · Cited by 6
“The choice was driven by the necessity to keep such a model as simple as possible, to favor both the a priori and the a posteriori identifiability, but also to make the model easy to incorporate in the UVa/Padova T1D Simulator, as done in [26,27].”
MethodSelf-citation
Metadata
- Authors
- Schiavon, M., Visentin, R., Giegerich, C., Sieber, J., Dalla Man, C., Cobelli, C., & Klabunde, T.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2020-08-01
- Volume
- 22
- Issue
- 8
- Pages
- 553-561
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2907081153
- Cited by
- 19
- References
- 17
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes. https://app.cochat.ai/papers/10.1089/dia.2020.0027
- The paper
- Schiavon, M., Visentin, R., Giegerich, C., Sieber, J., Dalla Man, C., Cobelli, C., & Klabunde, T. (2020). In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2020.0027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.